3 / 5
Volume 5, Issue 7 (Suppl)
J Infect Dis Ther, an open access journal
ISSN: 2332-0877
Infection Prevention 2017
December 14-15, 2017
Page 17
conference
series
.com
December 14-15, 2017 | Rome, Italy
13
th
World Congress on
INFECTION PREVENTION AND CONTROL
Lbachir BenMohamed, J Infect Dis Ther 2017, 5:7(Suppl)
DOI: 10.4172/2332-0877-C1-034
Bolstering the number and function of hsv-1-specific cd8+ TEM and TRM cells in latently infected
trigeminal ganglia reduces recurrent ocular herpes infection and diseases
H
erpes simplex virus type 1 (HSV-1) is a prevalent human pathogen that infects over 3.72 billion individuals worldwide
and can cause potentially blinding recurrent corneal herpetic disease. HSV-1 establishes latency within sensory neurons
of trigeminal ganglia (TG) and TG-resident CD8+ T cells play a critical role in preventing its reactivation. The repertoire,
phenotype and function of protective CD8+ T cells are unknown. Bolstering the apparent feeble numbers of CD8+ T cells in
TG remains a challenge for immunotherapeutic strategies. In this study, a comprehensive panel of 467 HLA-A*0201-restricted
CD8+ T cell epitopes were predicted from the entire HSV-1 genome. CD8+ T cell responses to these genome-wide epitopes
were compared in HSV-1 seropositive symptomatic (SYMP) individuals (with a history of numerous episodes of recurrent
herpetic disease) vs. asymptomatic (ASYMP) individuals (who are infected but never experienced any recurrent herpetic
disease). Frequent polyfunctional HSV-specific effector memory IFN-+CD107a/b+CD44highCD62LlowCD8+ TEM cells were
detected in ASYMP individuals and were mainly directed against three “ASYMP” epitopes. In contrast, SYMP individuals have
more mono-functional central memory CD44highCD62LhighCD8+ TCM cells. Furthermore, therapeutic immunization with
an innovative prime/pull vaccine, based on priming with multiple “ASYMP” epitopes (prime) and neurotropic TG delivery of
the T-cell attracting chemokine CXCL-10 (pull), boosted the number and function of CD44highCD62LlowCD8+ TEM and
tissue-resident CD103highCD8+ TRM cells in TG of latently infected HLA-A*0201 Tg mice and reduced recurrent ocular
herpes following UV-B induced reactivation. These findings have profound implications in the development of T-cell-based
immunotherapeutic strategies to treat blinding recurrent herpes infection and disease.
Footnotes:
This work is supported by Public Health Service Research R01 Grants EY026103, EY019896 and EY024618 from
National Eye Institute (NEI) and R21 Grant AI110902 from National Institutes of allergy and Infectious Diseases (NIAID), by
The Discovery Center for Eye Research (DCER) and by a Research to Prevent Blindness (RPB) grant.
Biography
BenMohamed is a Professor of Immunology, the founder and the head of the Laboratory of Cellular and Molecular Immunology in the Department of Ophthalmology at the
University of California. He also holds a joint appointment with the Center of Immunology at UC Irvine and with Chao Family Comprehensive Cancer Center UCI Medical
center. Dr. BenMohamed received his Ph.D. in Immunology from the Pasteur Institute, Paris, France in 1997 where he worked as the key developer and co-inventor of
a new promising vaccine strategy that uses mucosal delivery of clinically approved lipopeptide molecules. Dr. BenMohamed has been involved in clinical immunology,
humoral and cellular immune responses, epitope mapping, epitope improvement, and the development and optimization of sub-unit vaccines against several infectious
diseases including malaria Plasmodium falciparum, human immunodeficiency virus (HIV), human cytomegalovirus (HCMV) and herpes simplex virus type 1 and type
2 (HSV-1 and HSV-2). Dr. BenMohamed is an independent immunologist, with a national and international reputation in vaccine development against both infectious
diseases and cancer. Dr. BenMohamed is well integrated into the scientific community within the United States as well as Europe and is actively involved in a number
of professional societies including American Association of Immunologists (AAI), American Society for Microbiology (ASM), American Society for Hematology (ASH),
Association for Research in Vision and Ophthalmology (ARVO).
wmazi@moh.gov.saLbachir BenMohamed
University of California, USA